“Close enough,” he tells the scientist. “From here on in, it’s who you know.” Howard Scott, a freelance writer in Pembroke and longtime subscriber to The New Yorker and the Globe, said he saw the cartoon at breakfast and thought it bore an uncanny resemblance to an old New Yorker cartoon. He has dozens displayed on the walls of his home office. “I looked at the picture and I said, ‘My God, I know that cartoon,’ ” Scott, 75, said. “I went to my office three steps away.” There, on his wall, was the one he had in mind. It was drawn by Eldon Dedini and depicted two men standing in almost the identical position in front a blackboard covered with mathematical equations. “This is fine as far as it goes,” one man, with his arms crossed, told the other. “From here on, it’s who you know.” Scott included both cartoons in a letter to the Globe and wrote, “What is the line of cartoon … [Read more...] about Did a biotech exec crib a New Yorker cartoon?
Teamwork helped Laura Shawver, the Synthorx CEO, through the long, exhausting days on the road show. Sometimes she couldn’t sleep and sent emails to her IPO team. “You know you have the right team when you send an mail at two or three in the morning, and they email you back,” Shawver said. That team enables Shawver, a beach fan and surfer, to carve out some personal time outside of normal work hours, especially on weekends. “Sometimes I just don’t have my phone with me,” Shawver said. “That can be for a Saturday, it could be for an evening. Of course it can’t be for much longer than that. But to not have your phone with you all the time is important.” “I still go to the beach most mornings when I’m in town,” she said. “It doesn’t mean that I surf every morning, but I’m lucky enough to live close to the beach.” Synthorx completed its IPO in early December, selling 13.7 million shares at … [Read more...] about 3 paths to becoming a successful female biotech CEO
By Tat Dinh  June 1, 2019 | 07:09 pm GMT+7 A section of Hanoi's To Lich River being treated using biotechnology. Photo by VnExpress/Tat Dinh. Authorities are hopeful that water quality in Hanoi’s infamous To Lich River will become good enough to breed fish. Their hope stems from the quality improvements seen a week after a nano-biotech treatment was applied, beginning May 16. Specifically, the amount of ammonia in the river, which made it stink, reduced drastically three days after the Nano-Bioreactor technology was used, said Nguyen Tuan Anh, chairman of the Japan-Vietnam Environmental Improvement Company (JVE) which is carrying out the pilot project. He said Friday that the sludge at the bottom of the river had also partly decomposed a week after, producing a layer of clear water above it. "These results are announced only for experts to know of changes to the initial metrics, so we are not going into details. Scientifically speaking, water quality … [Read more...] about Hanoi improves To Lich River water with nano-biotech application
Vividion Therapeutics, a developer of drugs for cancer and immune diseases, has raised $82 million, the San Diego biotech said Tuesday.The Series B financing will help privately held Vividion find drugs to reach proteins involved in diseases. Most of these proteins can’t be affected by drugs; in pharma-speak they are “undruggable” targets.The company was founded in 2014 by a team led by Scripps Research professor Benjamin Cravatt and fellow Scripps Research colleagues Phil Baran and Jin-Quan Yu. The three had worked on the “undruggable” problem from complementary angles, providing Vividion with a wide range of options.Success would not only benefit investors and patients, but also Scripps Research, which licensed the technology to Vividion.Vividion previously raised $45 million in 2017, and $101 million in a 2018 collaboration with Celgene, said Dr. Diego Miralles, Vividion’s CEO. That brings Vividion’s financing to $228 million.Of that total, … [Read more...] about San Diego biotech Vividion raises $82 million
Updated 9:06 pm PST, Tuesday, February 26, 2019 FILE - In this Oct. 9, 2018, file photo, Zhou Xiaoqin installs a fine glass pipette into a sperm injection microscope in preparation for injecting embryos with Cas9 protein and PCSK9 sgRNA at a lab in Shenzhen in southern China's Guandong province. China has unveiled draft regulations on gene-editing and other new biomedical technologies it considers to be "high-risk." The measures follow claims in November 2018 by Chinese scientist He Jiankui that he helped make the world's first genetically-edited babies. That roiled the global science community and elicited widespread outcry over the procedure's ethical implications. less FILE - In this Oct. 9, 2018, file photo, Zhou Xiaoqin installs a fine glass pipette into a sperm injection microscope in preparation for injecting embryos with Cas9 protein and PCSK9 sgRNA at a lab in Shenzhen ... more Photo: Mark Schiefelbein, … [Read more...] about China drafts rules on biotech after gene editing scandal